MORF240517P30000
- 2.65
- 0.000.00%
Morphic Newsroom
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule Α4β7 Inhibition of Gut-Trafficking Cells
Supporting Materials: Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclona... Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclona...-α4
Morphic Ethical Funds Continues Share Buy-Back
Morphic Fund's Buyback Plan Wins Strong Approval
Morphic Fund Announces Upcoming Dividend
Morphic Fund Navigates Ethical Investing Amid Market Volatility
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chron
Morphic Ethical Continues Share Buy-Back
Morphic Fund Advances Share Buy-Back Effort
Morphic Ethical Fund Continues Stock Buy-Back
Future Generation's Holdings Decrease in Morphic Fund
Morphic Fund Reports Change in Major Shareholder
Morphic Ethical Fund Continues Share Buy-Back
Morphic Ethical Equities Continues Share Buy-Back
Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)
Morphic Fund Completes Share Buy-Back
Morphic Holding Launches New Stock Offering, Ends Previous Deal
Express News | Morphic - May Offer and Sell, From Time to Time at Its Sole Discretion, Shares of Its Common Stock, Having Price of up to $350 Mln
Express News | Morphic Holding Inc - Entered Into a Sales Agreement With TD Securities (USA) LLC
Morphic Holding Files Automatic Mixed Shelf